147 related articles for article (PubMed ID: 37766881)
1. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
Miao W; Guo J; Cheng H; Zhao Q
Infect Drug Resist; 2023; 16():6277-6284. PubMed ID: 37766881
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
3. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Coagulation Function in Patients Receiving Aspirin and Cefoperazone-Sulbactam With and Without Vitamin K
Wu S; Wu G; Wu H
Clin Ther; 2021 Dec; 43(12):e335-e345. PubMed ID: 34819242
[TBL] [Abstract][Full Text] [Related]
5. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.
Wang W; Liu Y; Yu C; Tan J; Xiong W; Dong D; Li S; Zhang R; Li J; Wu Y; Zong Z; Su N; Zou K; Wu G; Sun X
Expert Opin Drug Saf; 2020 Mar; 19(3):339-347. PubMed ID: 31914329
[No Abstract] [Full Text] [Related]
6. Effect of Cefoperazone/Sulbactam on Blood Coagulation Function in Infected Emergency Department Patients and the Necessity of Vitamin K1 (VK1) Preventive Intervention: A Single-Center, Retrospective Analysis.
Shao X; Ren Y; Xie N; Fan K; Sun H; Lu J; Wei J; Tian X
Med Sci Monit; 2023 Jun; 29():e939203. PubMed ID: 37271979
[TBL] [Abstract][Full Text] [Related]
7. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
Wang Q; Huang M; Zhou S
J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
[TBL] [Abstract][Full Text] [Related]
8. Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections.
Li Y; Xie J; Chen L; Meng T; Liu L; Hao R; Dong H; Wang X; Dong Y
Pak J Pharm Sci; 2020 Jan; 33(1):161-168. PubMed ID: 32122844
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
10. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R; Gao L; Chen P; Liu W; Huang X; Li X
Front Pharmacol; 2023; 14():1170987. PubMed ID: 37361226
[No Abstract] [Full Text] [Related]
11. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
13. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.
Xin X; Jian L; Xia X; Jia B; Huang W; Li C; Wang C; Zhou L; Sun X; Tang X; Huang Y; Zhu Y; Zhang W
Ann Clin Microbiol Antimicrob; 2013 Dec; 12():38. PubMed ID: 24321187
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Influencing Factors of Coagulation Dysfunction Caused by Cefoperazone/Sulbactam.
Zeng J; Zou M; Min M; Xu M
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38290444
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii.
Qin Y; Zhang J; Wu L; Zhang D; Fu L; Xue X
Int J Clin Pharmacol Ther; 2018 Mar; 56(3):120-129. PubMed ID: 29319497
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant
Gu S; Xiong J; Peng S; Hu L; Zhu H; Xiao Y; Luo H; Hang Y; Chen Y; Fang X; Cao X; Fang Y; Li F; Zhu J; Zhong Q
Infect Drug Resist; 2023; 16():2589-2600. PubMed ID: 37152405
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients.
Bai H; Li H; Nie X; Yao Y; Han X; Wang J; Peng L
PLoS One; 2023; 18(9):e0291658. PubMed ID: 37733780
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
Liu B; Bai Y; Liu Y; Di X; Zhang X; Wang R; Wang J
J Chemother; 2015 Oct; 27(5):271-6. PubMed ID: 25068186
[TBL] [Abstract][Full Text] [Related]
19. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms.
Rice LB; Carias LL; Etter L; Shlaes DM
Antimicrob Agents Chemother; 1993 May; 37(5):1061-4. PubMed ID: 8390809
[TBL] [Abstract][Full Text] [Related]
20. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]